Pharmaceutical industry – Page 50
-
News
Radical drug rule changes hit buffers in India
Oversight panel concludes government plan will increase bureaucracy
-
Business
Novartis in the spotlight in mis-selling investigations
Crackdown on pharma marketing continues with US and Japanese cases
-
OpinionIs there a drug for that?
Derek Lowe ponders whether anything is truly ‘undruggable’ if we look in the right places
-
-
Business
AstraZeneca claims quashed in heartburn drug patent case
Nexium rival does not infringe on patent, court rules
-
Business
Chinese police seize £222m of fake drugs
1300 people are arrested in a nationwide crackdown on counterfeit medicines
-
Business
AstraZeneca shells out $4.1bn for diabetes business
Bristol-Myers Squibb exits the diabetes field with plans to become a specialised biopharmaceutical company
-
Opinion
Cut price pills cost more than pennies
We can’t afford to let the demand for cheaper medicines force compromises on quality, says Steven Ford
-
BusinessNew wave of hepatitis C drugs hits US shore
J&J’s once-daily drug approved by FDA, but rivals are hot on its heels
-
Business
US turnaround on Avandia restrictions
Researchers accuse regulator of face-saving U-turn over diabetes medication safety
-
OpinionPut the chemistry back in medicinal chemistry
Pursuing skewed priorities and easy options has impoverished the pharmaceutical industry, says David Lathbury.
-
OpinionRolling boulders uphill
Is Derek Lowe troubled by his failure to develop a compound that has made it to the pharmacy shelf?
-
Business
Regulator cracks down on 23andMe
Personal genetic profiler ordered to stop selling DNA test kits
-
Business
Pfizer teams up with GSK in cancer drug trial
Two companies will collaborate to develop a combination therapy for melanoma
-
FeatureGeneric problems
The Indian pharmaceutical industry has been hit by recent problems. Angeli Mehta investigates
-
Business
DSM to spin out pharma unit
Firm will combine with Patheon to provide manufacturing services
-
Business
Novartis sells off blood diagnostics division
$1.7bn deal reinforces firm’s focus on core pharmaceuticals
-
CareersThe pain killer
Life is pretty painless working in Reckitt Benckiser’s Nurofen team, Sarah Houlton learns